Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 19, 2025
Product Development
Tempus aims for precision in complexity
With clinical records, patient samples and images in the millions, the diagnostics and data company is betting precision medicine can go multimodal
BioCentury | May 29, 2024
Discovery & Translation
Science Spotlight: Cimeio’s cell-shielding technology, stopping EBV-driven cancer and more
BioCentury’s roundup of translational innovations
BioCentury | Dec 7, 2023
Product Development
The first-in-human immuno-oncology problem
Companies face growing challenges in deciding whether to advance an immuno-oncology program based on early Phase I data
BioCentury | Jun 8, 2023
Discovery & Translation
Modalities, not targets, drive translational innovation at ASCO23
BioCentury’s analysis of first-in-human studies at ASCO 2023
BioCentury | May 13, 2022
Data Byte
Distillery spotlight on Italian innovation
Opportunities include compounds and targets for cancer, neurology and musculoskeletal diseases, and discoveries from company founders
BioCentury | Mar 24, 2022
Discovery & Translation
IDO thwarts antitumor T cell responses; plus Lumen, Loki, Genentech and more
BioCentury’s roundup of translational news
BioCentury | Feb 19, 2022
Data Byte
Moderna’s mRNA vaccine adds to a short IDO pipeline
Moderna’s candidate aims to stimulate T cell responses to IDO1 and PD-L1
BioCentury | Feb 19, 2022
Product Development
Feb. 18 Quick Takes: $200M to ease Synthego into gene, cell therapy
Plus updates from Atara, Moderna, Regeneron, Agios, GSK, BioMarin, Bayer, Intellia-ONK, Merck KGaA, Blue Water
BioCentury | Aug 27, 2021
Distillery Therapeutics
A tryptophan catabolite to treat psoriasis and nephritis
Items per page:
1 - 10 of 127